MBRX — WP1066 and Radiation Therapy Phase 2 Trial Completion in Glioblastoma
Dec 27, 2028, 5:00:00 AM UTC
Summary
A Phase 2 clinical trial evaluating WP1066, a STAT3 inhibitor, in combination with radiation therapy for newly diagnosed glioblastoma is expected to complete on December 27, 2028. The study, sponsored by Northwestern University, focuses on progression-free survival, tumor microenvironment changes, and safety in patients with MGMT-unmethylated glioblastoma. WP1066 is an investigational oral immunomodulatory agent targeting the STAT3 pathway, aiming to improve outcomes in malignant gliomas. The trial is registered as NCT05879250 and is currently recruiting.
Company
MOLECULIN BIOTECH INC (MBRX)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.moleculin.comSimilar Events
Phase 2a Immune Modulation With Ultrasound Clinical Trial Completion
A Phase 2a clinical trial evaluating immune modulation with ultrasound for newly diagnosed glioblastoma is expected to complete on August 1, 2026. The study, sponsored by Northwestern University, investigates the Soncloud-9 device in combination with balstilimab, botensilimab, and liposomal doxorubicin. The trial aims to assess safety and efficacy of this novel approach to enhance drug delivery across the blood-brain barrier. Agenus (AGEN) is associated with the trial through its immunotherapy agents. Glioblastoma is an aggressive brain cancer with limited treatment options.
trial completionCR6086/AGEN2034 Combination Clinical Trial Completion
A Phase 1/2 clinical trial evaluating the combination of CR6086 (vorbipiprant), an EP4 receptor antagonist, and AGEN2034 (balstilimab), an anti-PD-1 antibody, in patients with stage IV pMMR-MSS colorectal cancer and other metastatic gastrointestinal cancers is expected to complete by September 1, 2026. The study, sponsored by Rottapharm Biotech, aims to assess the safety and efficacy of combining targeted immunomodulation with immune checkpoint inhibition in refractory GI malignancies. Enrollment is ongoing with a target of 55 participants.
trial completionCompletion of Glioblastoma Biomarker Study Using TTFields
A clinical trial sponsored by Institut Claudius Regaud, involving 80 patients with newly diagnosed glioblastoma, is expected to complete by October 1, 2027. The study aims to identify biomarkers of response and resistance to Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment modality. Patients will receive standard radio-chemotherapy followed by TTFields, with serial blood and tumor samples collected for analysis. The Optune system, a battery-operated device delivering TTFields, is used in routine care but is not under investigation in this study. The trial's findings may inform future patient selection and therapeutic strategies for glioblastoma.
trial completionPhase II Immunotherapy Combination Trial in Colorectal Cancer Liver Metastases Completion
A phase II clinical trial evaluating immunotherapy combinations, including botensilimab, balstilimab, and AGEN1423, with or without radiation, in patients with colorectal cancer liver metastases is expected to complete by March 1, 2027. The study, sponsored by Weill Medical College of Cornell University, aims to assess immunological changes in the tumor microenvironment and inform further development of these investigational agents. The trial is currently recruiting and targets 24 participants.
trial completion